Monoamine precursors in the treatment of depression

The current biological theories of depression are united in postulating a role for brain monoamine deficiency in this group of disorders. The relative importance of the various amines, dopamine (DA), norepinephrine ( NE ), serotonin (5–HT ) and tryptamine, is still unsettled, and several versions of the monoamine deficit theory of depression have been put forward with emphasis on one or other of these compounds.5, 56, 94, 128

[1]  Murray Tj.  L-dopa therapy in Parkinson's disease. , 1972 .

[2]  M. Goldsztajn,et al.  [L-dopa in the treatment of parkinsonism]. , 1971, Przeglad lekarski.

[3]  B. Carroll,et al.  Rubidium and Lithium: Opposite Effects on Amine-Mediated Excitement , 1971, Science.

[4]  B. Carroll,et al.  L-tryptophan as an antidepressant. , 1971, Lancet.

[5]  E. S. Roth,et al.  Inhibition of tyrosine aminotransferase activity by L-3,4-dihydroxyphenylalanine. , 1971, Biochemistry.

[6]  D. Murphy,et al.  Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. , 1971, The American journal of psychiatry.

[7]  S. Fahn,et al.  Mental effects of high-dosage levodopa. , 1971, Archives of general psychiatry.

[8]  M. Vogt,et al.  The effect of parachlorophenylalanine on the behaviour of cats , 1970, British journal of pharmacology.

[9]  S. Snyder,et al.  Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. , 1970, The Journal of pharmacology and experimental therapeutics.

[10]  D. Kupfer,et al.  Effects of L-tryptophan (a natural sedative) on human sleep. , 1970, Lancet.

[11]  R. Herson.  Mental symptoms in parkinsonian patients treated with L-dopa. , 1970, Lancet.

[12]  T. Chase,et al.  L-Dopa-Induced Release of Cerebral Monoamines , 1970, Science.

[13]  W. Lovenberg,et al.  Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. , 1970, Annals of internal medicine.

[14]  D. Murphy,et al.  L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. , 1970, Biological psychiatry.

[15]  A. Damasio,et al.  L-dopa, parkinsonism, and depression. , 1970, Lancet.

[16]  W. Bunney.  Present status of psychological reactions to L-DOPA. , 1970, The American journal of psychiatry.

[17]  G. Celesia,et al.  Psychosis and other psychiatric manifestations of levodopa therapy. , 1970, Archives of neurology.

[18]  R. Wurtman,et al.  The fate of C14-dihydroxyphenylalanine (C14-dopa) in the whole mouse. , 1970, The Journal of pharmacology and experimental therapeutics.

[19]  D. Laurence,et al.  Monoamine oxidase inhibitors and L-dopa. , 1970, British medical journal.

[20]  U. Ungerstedt,et al.  Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. , 1970, European journal of pharmacology.

[21]  S. Merlis,et al.  The action of L-dopa on schizophrenic patients (a preliminary report). , 1970, Current therapeutic research, clinical and experimental.

[22]  R. Baldessarini,et al.  L-Dihydroxyphenylalanine: Effect on S-Adenosylmethionine in Brain , 1970, Science.

[23]  E. Azmitia,et al.  In vivo Conversion of 3H-L-Tryptophan into 3H-Serotonin in Brain Areas of Adrenalectomized Rats , 1970, Science.

[24]  L. Kier,et al.  The preferred conformation of dopamine from molecular orbital theory. , 1970, The Journal of pharmacology and experimental therapeutics.

[25]  R. Wohlhueter,et al.  Effects of ingestion of disproportionate amounts of amino acids. , 1970, Physiological reviews.

[26]  I. Khan,et al.  The metabolism of L-3,4-dihydroxyphenylalanine in man. , 1970, Clinica chimica acta; international journal of clinical chemistry.

[27]  M. A. Cocheme.  L-tryptophan versus E.C.T. , 1970, The Lancet.

[28]  W. J. Nowack,et al.  Brain norepinephrine: Enhanced turnover after rubidium treatment , 1970, Science.

[29]  G. Everett,et al.  L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice , 1970, Science.

[30]  B. Carroll,et al.  Sequential comparison of L-tryptophan with E.C.T. in severe depression. , 1970, Lancet.

[31]  M. Carino,et al.  Modification of the toxic actions of l-tryptophan by pargyline and p-chlorophenylalanine. , 1970, Biochemical pharmacology.

[32]  R. Wurtman,et al.  Daily rhythm in the accumulation of brain catechol-amines synthesized fom circulating H3-tyrosine. , 1970, The Journal of pharmacology and experimental therapeutics.

[33]  H. Loh,et al.  The effect of prolonged lithium treatment on the synthesis rate and turnover of monoamines in brain regions of rats. , 1970, European journal of pharmacology.

[34]  G. Ashcroft,et al.  Effect of tryptophan administration on 5HIAA in cerebrospinal fluid in man. , 1970, Journal of neurology, neurosurgery, and psychiatry.

[35]  J. Korf,et al.  5-Hydroxyindoleacetic Acid Levels in the Cerebrospinal Fluid of Depressive Patients treated with Probenecid , 1970, Nature.

[36]  E. Eidelberg,et al.  Possible Mechanism of Action of Morphine on Brain , 1970, Nature.

[37]  M. Youdim,et al.  Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase , 1970, Nature.

[38]  D. Murphy,et al.  L-dopa in depressed patients. , 1970, Lancet.

[39]  A. Coppen.  The chemical pathology of the affective disorders. , 1970, The Scientific basis of medicine annual reviews.

[40]  H. V. van Praag.  Indoleamines and the central nervous system; a sounding of their clinical significance. , 1970, Psychiatria, neurologia, neurochirurgia.

[41]  D. Shaw.  L-tryptophan in depression. , 1970, Lancet.

[42]  G. C. Cotzias,et al.  Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. , 1970, New England Journal of Medicine.

[43]  E. Azmitia,et al.  Corticosterone Regulation of Tryptophan Hydroxylase in Midbrain of the Rat , 1969, Science.

[44]  G. Nisticó,et al.  Brain and liver tryptophan pathways and adrenocortical activation during restraint stress , 1969 .

[45]  S. Platman,et al.  Potentiation of a monoamine oxidase inhibitor by tryptophan. , 1969, Journal of psychiatric research.

[46]  R. Duvoisin,et al.  Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.

[47]  R. Daroff,et al.  Depression during L-dopa treatment. , 1969, Lancet.

[48]  L. Butcher,et al.  Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition. , 1969, Brain research.

[49]  D. Calne,et al.  The metabolism of orally administered l‐DOPA in Parkinsonism , 1969, British journal of pharmacology.

[50]  J. Schildkraut.  Neuropsychopharmacology and the Affective Disorders , 1969 .

[51]  J. M. Price,et al.  Tryptophan metabolism in patients with bladder cancer: geographical differences. , 1969, Journal of the National Cancer Institute.

[52]  C. Scheckel,et al.  HYPERACTIVE STATES RELATED TO THE METABOLISM OF NOREPINEPHRINE AND SIMILAR BIOCHEMICALS , 1969, Annals of the New York Academy of Sciences.

[53]  B. W. Logan,et al.  Further studies on the inhibition of monoamine oxidase by M and B 9302 (clorgyline). I. Substrate specificity in various mammalian species. , 1969, Biochemical pharmacology.

[54]  L. L. Miller,et al.  The functional significance of changes in activity of the enzymes, tryptophan pyrrolase and tyrosine transaminase, after induction in intact rats and in the isolated, perfused rat liver. , 1969, The Journal of biological chemistry.

[55]  George C. Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[56]  G. Oxenkrug,et al.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. , 1969, Lancet.

[57]  R. Duvoisin,et al.  Pyridoxine reversal of L-dopa effects in Parkinsonism. , 1969, Transactions of the American Neurological Association.

[58]  D. Rose.  Effect of ovarian hormones and oral contraceptives on tryptophan metabolism , 1969 .

[59]  A. R. Green,et al.  Decrease of 5-Hydroxytryptamine in the Brain provoked by Hydrocortisone and its Prevention by Allopurinol , 1968, Nature.

[60]  B. Waldeck,et al.  Effect of protripryline on the formation of [3H] noradrenaline from [3H] dopa , 1968, The Journal of pharmacy and pharmacology.

[61]  T. Chase,et al.  Evoked Release of Norepinephrine and Serotonin from Brain Slices: Inhibition by Lithium , 1968, Science.

[62]  D. Eccleston,et al.  THE EFFECTS OF PRECURSOR LOADING IN THE CEREBRAL METABOLISM OF 5‐HYDROXYINDOLES , 1968, Journal of neurochemistry.

[63]  J. Maas,et al.  In vivo studies of the metabolism of norepinephrine in the central nervous system. , 1968, The Journal of pharmacology and experimental therapeutics.

[64]  R. Wurtman,et al.  Daily rhythms in the concentrations of various amino acids in human plasma. , 1968, The New England journal of medicine.

[65]  W. Dewhurst.  New Theory of Cerebral Amine Function and its Clinical Application , 1968, Nature.

[66]  A. Pletscher,et al.  Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. , 1968, The Journal of pharmacology and experimental therapeutics.

[67]  D. Hertz,et al.  Preventing depression with tryptophan. , 1968, Lancet.

[68]  A. Pletscher,et al.  Decrease of cerebral 5‐hydroxytryptamine by 3,4‐dihydroxyphenylalanine after inhibition of extracerebral decarboxylase , 1968, The Journal of pharmacy and pharmacology.

[69]  W. Lovenberg,et al.  Tryptophan hydroxylation in mammalian systems. , 1968, Advances in pharmacology.

[70]  A. Coppen,et al.  Tryptophan in the treatment of depression. , 1967, Lancet.

[71]  R. Rubin.  Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. , 1967, Archives of general psychiatry.

[72]  P. Leyburn.  A critical look at antidepressant drug trials. , 1967, Lancet.

[73]  T. Hökfelt,et al.  Increased impulse flow in bulbospinal noradrenaline neurons produced by catecholamine receptor blocking agents. , 1967, European journal of pharmacology.

[74]  F. Goodwin,et al.  Effect of Lithium on the Uptake of Noradrenaline by Synaptosomes , 1967, Nature.

[75]  J. Carranza-Acevedo.  Oral contraceptives and depression. , 1967, Lancet.

[76]  R. Paine,et al.  Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. , 1967, Lancet.

[77]  W. Lichtensteiger,et al.  UPTAKE OF 5‐HYDROXYTRYPTAMINE AND 5‐HYDROXYTRYPTOPHAN BY NEURONS OF THE CENTRAL NERVOUS SYSTEM NORMALLY CONTAINING CATECHOLAMINES * , 1967, Journal of neurochemistry.

[78]  U. Ungerstedt,et al.  Localization of 5‐hydroxytryptamine uptake in rat brain after intraventricular injection , 1967, The Journal of pharmacy and pharmacology.

[79]  D. Richter.  TRYPTOPHAN METABOLISM IN MENTAL ILLNESS , 1967 .

[80]  A. Lundberg,et al.  The effect of DOPA on the spinal cord. 2. A pharmacological analysis. , 1966, Acta physiologica Scandinavica.

[81]  K. Fuxe,et al.  Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. , 1966, Acta physiologica Scandinavica.

[82]  J. Schildkraut,et al.  The effects of lithium ion on H3-norepinephrine metabolism in brain. , 1966, Life sciences.

[83]  Å. Bertler,et al.  The localization of monoaminergic blood-brain barrier mechanisms. , 1966, Pharmacological reviews.

[84]  C. Cazzullo,et al.  Tryptophan Metabolism in Affective Psychoses , 1966, British Journal of Psychiatry.

[85]  J. Schildkraut,et al.  The catecholamine hypothesis of affective disorders: a review of supporting evidence. , 1965, The American journal of psychiatry.

[86]  G. Klerman,et al.  CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS. , 1965, Pharmacological reviews.

[87]  G. Simpson,et al.  FURTHER STUDIES ON: ONE DAY TREATMENT OF DEPRESSION WITH 5-HTP. , 1964, The American journal of psychiatry.

[88]  A. Sjoerdsma,et al.  Reduction of the central effects of tryptophan by a decarboxylase inhibitor , 1964, Clinical pharmacology and therapeutics.

[89]  A. Carlsson.  FUNCTIONAL SIGNIFICANCE OF DRUG-INDUCED CHANGES IN BRAIN MONOAMINE LEVELS , 1964 .

[90]  G. Klerman,et al.  CLINICAL EXPERIENCE WITH DIHYDROXYPHENYLALANINE (DOPA) IN DEPRESSION. , 1963, Journal of psychiatric research.

[91]  C. Pare.  POTENTIATION OF MONOAMINE-OXIDASE INHIBITORS BY TRYPTOPHAN. , 1963, Lancet.

[92]  N. Kline,et al.  Relief of depression within one day using an M.A.O. inhibitor and intravenous 5-HTP. , 1963, The American journal of psychiatry.

[93]  A. Coppen,et al.  Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. , 1963, Lancet.

[94]  W. Bunney,et al.  Methods for reliable longitudinal observation of behavior. , 1963, Archives of general psychiatry.

[95]  T. Ellison,et al.  Effect of dietary phenylalanine and tryptophan upon rat brain amine levels. , 1962, The Journal of pharmacology and experimental therapeutics.

[96]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[97]  T. Sourkes,et al.  The action of some alpha-methyl and other amino acids on cerebral catecholamines. , 1961, Journal of Neurochemistry.

[98]  T. Chruściel,et al.  The decarboxylation of amino acids related to tyrosine and their awakening action in reserpine‐treated mice , 1960, The Journal of physiology.

[99]  A. Yuwiler,et al.  Studies on 5-hydroxytryptophan decarboxylase. I. In vitro inhibition and substrate interaction☆ , 1959 .

[100]  E. Boyland.  The biochemistry of cancer of the bladder. , 1958, British medical bulletin.

[101]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[102]  W. Knox,et al.  The hormonal control of tryptophan peroxidase in the rat. , 1955, The Journal of biological chemistry.

[103]  Knox We.  Two Mechanisms which Increase in vivo the Liver Tryptophan Peroxidase Activity: Specific Enzyme Adaptation and Stimulation of the Pituitary-Adrenal System , 1951 .

[104]  W. Knox.  Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system. , 1951, British journal of experimental pathology.

[105]  H. Blaschko,et al.  The formation of noradrenaline from dihydroxyphenylserine. , 1950, British journal of pharmacology and chemotherapy.